These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
751 related articles for article (PubMed ID: 34375715)
1. A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency. Leach A; Ilca FT; Akbar Z; Ferrari M; Bentley EM; Mattiuzzo G; Onuoha S; Miller A; Ali H; Rabbitts TH Antiviral Res; 2021 Oct; 194():105147. PubMed ID: 34375715 [TBL] [Abstract][Full Text] [Related]
2. A super-potent tetramerized ACE2 protein displays enhanced neutralization of SARS-CoV-2 virus infection. Miller A; Leach A; Thomas J; McAndrew C; Bentley E; Mattiuzzo G; John L; Mirazimi A; Harris G; Gamage N; Carr S; Ali H; Van Montfort R; Rabbitts T Sci Rep; 2021 May; 11(1):10617. PubMed ID: 34012108 [TBL] [Abstract][Full Text] [Related]
3. Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants. Ferrari M; Mekkaoui L; Ilca FT; Akbar Z; Bughda R; Lamb K; Ward K; Parekh F; Karattil R; Allen C; Wu P; Baldan V; Mattiuzzo G; Bentley EM; Takeuchi Y; Sillibourne J; Datta P; Kinna A; Pule M; Onuoha SC J Virol; 2021 Sep; 95(19):e0068521. PubMed ID: 34287040 [TBL] [Abstract][Full Text] [Related]
4. An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants. Tanaka S; Nelson G; Olson CA; Buzko O; Higashide W; Shin A; Gonzalez M; Taft J; Patel R; Buta S; Richardson A; Bogunovic D; Spilman P; Niazi K; Rabizadeh S; Soon-Shiong P Sci Rep; 2021 Jun; 11(1):12740. PubMed ID: 34140558 [TBL] [Abstract][Full Text] [Related]
5. Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics. Barton MI; MacGowan SA; Kutuzov MA; Dushek O; Barton GJ; van der Merwe PA Elife; 2021 Aug; 10():. PubMed ID: 34435953 [TBL] [Abstract][Full Text] [Related]
6. An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2. Tada T; Fan C; Chen JS; Kaur R; Stapleford KA; Gristick H; Dcosta BM; Wilen CB; Nimigean CM; Landau NR Cell Rep; 2020 Dec; 33(12):108528. PubMed ID: 33326798 [TBL] [Abstract][Full Text] [Related]
7. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants. Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770 [TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution. ZahradnĂk J; Marciano S; Shemesh M; Zoler E; Harari D; Chiaravalli J; Meyer B; Rudich Y; Li C; Marton I; Dym O; Elad N; Lewis MG; Andersen H; Gagne M; Seder RA; Douek DC; Schreiber G Nat Microbiol; 2021 Sep; 6(9):1188-1198. PubMed ID: 34400835 [TBL] [Abstract][Full Text] [Related]
9. An angiotensin-converting enzyme-2-derived heptapeptide GK-7 for SARS-CoV-2 spike blockade. Han S; Zhao G; Wei Z; Chen Y; Zhao J; He Y; He YJ; Gao J; Chen S; Du C; Wang T; Sun W; Huang Y; Wang C; Wang J Peptides; 2021 Nov; 145():170638. PubMed ID: 34419496 [TBL] [Abstract][Full Text] [Related]
10. High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses. Sims JJ; Lian S; Meggersee RL; Kasimsetty A; Wilson JM PLoS One; 2022; 17(8):e0271359. PubMed ID: 36006993 [TBL] [Abstract][Full Text] [Related]
11. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions. Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP mBio; 2021 Mar; 12(2):. PubMed ID: 33785634 [TBL] [Abstract][Full Text] [Related]
12. Shedding Light on the Inhibitory Mechanisms of SARS-CoV-1/CoV-2 Spike Proteins by ACE2-Designed Peptides. Freitas FC; Ferreira PHB; Favaro DC; Oliveira RJ J Chem Inf Model; 2021 Mar; 61(3):1226-1243. PubMed ID: 33619962 [TBL] [Abstract][Full Text] [Related]
13. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity. Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996 [TBL] [Abstract][Full Text] [Related]